Systemic Sclerosis clinical trials at UCSF
1 research study open to eligible people
Systemic sclerosis is a disease that causes hardening of the skin and other organs. UCSF is running a study to test the safety and effects of a drug called Vixarelimab in people with lung problems from this disease. This trial is currently looking for participants.
Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
open to eligible people ages 18-85
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Fresno, California and other locations
Last updated: